On the stock market since 2021, it operates in the world of health and science. It has 234 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $1.4B in the vault; even if every debt were paid off, $1.4B would remain.
A loss of $425.4M against $0 in annual sales.
Over the last 12 months, executives reported 365 sells against just 95 buys. Not an alarm bell by itself, but a number worth watching.
On our five-subject report card, NUVL sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NUVL is a high-risk stock — not yet profitable, and its future rides on its product catching on.